M1A.449

Clinical Causes: Chronic kidney disease impairs uric acid clearance from the body. Use of medications such as diuretics or low-dose aspirin can increase uric acid levels. Metabolic disorders that lead to excessive production of uric acid. Certain cancers or chemotherapy treatments that cause cell breakdown. Diet rich in purine-containing foods like red meats, shellfish, and alcohol. Obesity and metabolic syndrome which are associated with impaired uric acid processing.

Key Symptoms: Persistent swelling and tenderness in the affected finger joints. Repeated episodes of joint pain, often severe and sudden. Formation of tophi—small, chalky deposits of uric acid crystals under the skin around the joints. Limited range of motion in the affected hand due to joint damage or swelling. Skin over the joint may appear red, hot, and inflamed. Chronic joint deformity if gout episodes are frequent and untreated.

Diagnosis Path: Diagnosis involves a combination of clinical evaluation, medical history, and laboratory tests. The healthcare provider may perform a physical examination to assess joint swelling and tenderness, then order blood tests to measure serum uric acid levels. Imaging studies such as X-rays can reveal joint damage or tophi. In certain cases, joint fluid analysis is performed by extracting fluid from the affected joint to identify monosodium urate crystals under polarized light microscopy, confirming gout.

Treatment Protocols: Managing this form of gout aims to reduce inflammation, lower uric acid levels, and prevent joint damage. Typical strategies include: - Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) to control pain and inflammation. - Colchicine, particularly effective during acute attacks. - Corticosteroids may be prescribed when NSAIDs are contraindicated. - Long-term urate-lowering therapies like allopurinol or febuxostat to prevent future gout attacks. - Lifestyle modifications including dietary changes, weight management, and reducing alcohol intake. - Regular monitoring of uric acid levels to guide treatment adjustments. Collaboration with healthcare providers is essential for personalized management plans and to prevent progression of joint damage.